{"entity":{"id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","aka":[],"tldr":"Shunji Takahashi leads medical oncology and early-phase trials at Japan's oldest cancer institute.","summary":"Shunji Takahashi is Director of the Department of Medical Oncology at the Cancer Institute Hospital of JFCR, Japan's oldest cancer institute. He leads medical oncology and early-phase trials there, running phase 1 and rare-cancer studies, including sarcoma, and the hospital's genomic medicine programme built on comprehensive genomic profiling. His publications include a phase 1 study of the MDM2 inhibitor milademetan in Japanese patients with solid tumours, a phase 1 study of dasatinib in Japanese patients with solid tumours, and an integrated analysis of osteonecrosis of the jaw across three phase 3 trials in patients with bone metastases. His interests are phase 1 trials, rare cancers and genomic medicine.","asOf":"2026-09-08","links":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Takahashi%20S%5BAuthor%5D%20Cancer%20Institute%20Hospital%20JFCR"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["jfcr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-science"],"dependsOn":[],"notes":[],"role":"Director, Department of Medical Oncology, Cancer Institute Hospital of JFCR","institutionId":"jfcr","specialisms":["Medical oncology","Phase 1 trials","Rare cancers","Genomic medicine"],"profiles":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Takahashi%20S%5BAuthor%5D%20Cancer%20Institute%20Hospital%20JFCR"}],"papers":[{"title":"Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study","journal":"Cancer Science","year":2021,"doi":"10.1111/cas.14875"},{"title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","journal":"Annals of Oncology","year":2012,"doi":"10.1093/annonc/mdr435"},{"title":"Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors","journal":"Cancer Science","year":2011,"doi":"10.1111/j.1349-7006.2011.02041.x"}]},"route":"/people/takahashi-shunji/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"institution":[{"id":"jfcr","kind":"institution","name":"Cancer Institute Hospital of JFCR","route":"/institutions/jfcr/"}],"journal":[{"id":"cancer-science","kind":"journal","name":"Cancer science","route":"/journals/cancer-science/"}]}}